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Abstract
This study was undertaken to develop a composite measure that combines the discriminant values 
of individual laboratory markers routinely used for excessive alcohol use (EAU) for an improved 
screening performance. The training sample consisted of 272 individuals with known history of 
EAU and 210 non-alcoholic individuals. The validation sample included 100 EAU and 75 controls. 
We used the estimated regression coefficients and the observed marker values to calculate the 
individual’s composite screening score; this score was converted to a probability measure for 
excessive drinking in the given individual. A threshold value for the screening score based on an 
examination of the estimated sensitivity and specificity associated with different threshold values 
was proposed. Using regression coefficients estimated from the training sample, a composite score 
based on the levels of aspartate aminotransferase, alanine aminotransferase, per cent carbohydrate-
deficient transferrin and mean corpuscular volume was calculated. The areas under the receiver 
operating characteristic curve (AUC) value of the selected model was 0.87, indicating a strong 
discriminating power and the AUC was better than that of each individual test. The score >0.23 
corresponded to a sensitivity of 90% and a specificity of nearly 60%. The AUC value remained at 
a respectable level of 0.83 with the sensitivity and specificity at 91% and 49%, respectively, in the 
validation sample. We developed a novel composite score by using a combination of commonly 
used biomakers. However, the development of the mechanism-based biomarkers of EAU is needed 
to improve the screening and diagnosis of EAU in clinical practice.
INTRODUCTION
Excessive alcohol use is a major public health problem.1 Its incidence is on the rise with a 
parallel increase in the prevalence of alcohol-related diseases.23 Screening for excessive 
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alcohol use (EAU) in clinical setting is of importance, as early detection could lead to timely 
intervention to prevent subsequent adverse health outcomes.45
Excessive alcohol drinking is usually screened in clinical practice through patient interviews 
or questionnaires, by using validated instruments such as AUDIT,6 CAGE,78 or reports from 
collateral family with direct interaction with patients.4 Laboratory measures are also used to 
aid alcoholism screening: Among the most commonly used markers, mean corpuscular 
volume (MCV) has only a modest level of diagnostic sensitivity (approximately 50%).4 
Carbohydrate deficient transferrin (CDT) is generally more sensitive, as excessive alcohol 
consumption is known to lead to reduced number of carbohydrate residues attached to serum 
transferrin.910 The diagnostic accuracy of CDT, however, tends to vary greatly by clinical 
population, with sensitivity ranging from 53% to 80% in screening for subjects with chronic 
alcohol use.4910 Similarly, serum levels of hepatic enzymes γ-glutaryl transferase (GGT), 
aspartate aminotransferase (AST), and alanine aminotransferase (ALT) are also potential 
markers because their activities are known to be altered by excessive and prolonged 
alcoholic exposure.11 Our research team recently reported that levels of diagnostic 
sensitivity of GGT, AST and ALT were 50%, 27%, and 27%, respectively, for excess 
drinking screening,4 which were generally close to the 35–60% range reported by previous 
studies.12–14 Reports from our research team and those from others clearly highlight the 
insufficient diagnostic accuracy of these markers when they are used single markers for 
EAU. The purpose of the current research was to explore the development of a composite 
measure that combines the discriminant values of these individual laboratory markers for an 
improved screening performance.
METHODS
Study samples
Data from two separate groups of subjects were used to develop and to validate the 
composite screening measure. The training sample, that is, the group of participants whose 
data were used to develop the screener, consisted of 272 individuals with EAU (ie, cases), 
and 210 nonalcoholic individuals. These individuals were recruited from January 2012 to 
June 2014. The cases were patients admitted to Fairbanks Drug and Alcohol Treatment 
Center (Indianapolis, Indiana, USA) for alcohol rehabilitation. Enrolled cases met the 
criteria for ‘excessive drinking’; defined by NIH/NIAAA as men who drink more than four 
standard drinks in a day (or more than 14/week) and women who drink more than three 
standard drinks in a day (or more than 7/week). Patients reported the last use of alcohol 
within 0–72 h before enrollment. The non-excessive drinking participants were recruited 
from Richard L. Roudebush Veterans Administration Medical Center (RLR VAMC, 
Indianapolis, Indiana, USA). All study participants were aged at least 21 years. Individuals 
who had active and serious medical diseases (such as congestive heart failure, chronic 
obstructive pulmonary disease, cancer, uncontrolled diabetes, and chronic renal failure) at 
the time of screening, had a history of any systemic infection within 4 weeks prior to the 
study, or had a history of recent major surgeries within the past 3 months were excluded 
from study participation.
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The validation sample, that is, the group of individuals whose data were used to validate the 
diagnostic measure, included 100 excessive drinkers and 75 non-excessive drinkers. 
Participants in the validation sample were enrolled, independently from June 2013 to 
December 2014, from the previously described recruitment sites. The inclusion and 
exclusion criteria remained the same as those in the training sample. Participants in the two 
study samples provided written informed consent prior to study enrollment. A local 
institutional review board approved the study design and the patient enrollment and 
assessment protocol.
Data collection and clinical evaluation
All participants completed a self-administered questionnaire such as demographic data and 
AUDIT-C. The Time Line Follow-Back (TLFB) questionnaire was used to determine the 
amount of alcohol consumption over the 30-day period before the study date. It was 
administered in person by trained study coordinators who reviewed the instructions with the 
subjects prior to administering the questionnaire. The TLFB offers a retrospective report of 
daily alcohol consumption over the past 30 days; drinks per drinking occasion, and pattern 
of drinking can be computed.15 Blood samples were obtained for assay of commonly used 
markers to identify chronic alcohol use (such as GGT, CDT, AST, and ALT and MCV); 
samples were analyzed at the RLR VAMC.
Statistical analyses
Demographic and clinical characteristics of the study participants in the training and 
validation samples were summarized and described separately. Characteristics were 
compared between the cases and non-cases. Continuous variables were compared using 
Student t tests, including % CDT, levels of GGT, AST, ALT and MCV. Categorical variables 
were compared using χ2 tests.
The study sample was divided into two subsets: data from 70% of the subjects were used for 
model development and the rest for model validation. Within the development sample, we 
used multiple logistic regression models to classify the cases and non-cases. Individual 
markers were first examined for their discriminant power in simple logistic regression 
models. We then performed a stepwise model selection, starting with all five markers in the 
model. We used Akaike Information Criterion (AIC) to determine the superiority of the 
competing models. AIC is a measure for the quality of statistical models that balances the 
goodness-of-fit with model complexity. It is widely used for model selection in analytical 
practice.16 We chose the model with the smallest AIC value. For the competing models, we 
also examined the p values of the individual markers, as well as the areas under the receiver 
operating characteristic curve (AUC).17 In particular, we compared the AUC of all single 
marker models against that of the selected model using a non-parametric test.18 The receiver 
operating characteristic curve (ROC) of the final model was presented graphically. To ensure 
the numerical stability of the selected model, we examined all pairwise correlations and 
calculated variance inflation factor (VIF) associated with the final model. A larger VIF value 
typically indicates the presence of multicolinearity.19
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For a given individual, we used the estimated regression coefficients and the observed 
marker values to calculate the individual’s composite screening score; this score was 
converted to a probability measure for excessive drinking in the given individual. We 
proposed a threshold value for the screening score based on an examination of the estimated 
sensitivity and specificity associated with different threshold values. Details of the score 
calculation and corresponding sensitivity and specificity were reported in the Results 
section.
To validate the proposed composite screening score, we calculated the AUC value of the 
model in the validation sample. Using the previously identified threshold value, we 
classified all subjects in the validation sample either as cases or as non-cases. We then 
calculated and reported the levels of sensitivity and specificity of the composite screener, as 
well as its positive and negative predictive values, in the validation sample. As expected, the 
AUC values were sample-specific. For a more accurate assessment of the predictive 
performance, we conduct a cross-validation study by resampling the original sample 20 
times, for each resample, we divide the data into model development subset and validation 
subset. The mean AUC values based on the resampled data were obtained and reported.
RESULTS
Demographic and clinical characteristics of training and verification cohorts
The detailed demographic and clinical characteristics for training and validation samples are 
presented in tables 1 and 2. For the training sample, excessive drinkers were older (39.7 vs 
32.5 years, p<0.001), had higher percentage of divorce/separation (28% vs 18%, p=0.0001), 
and had lower BMI (27.8 vs 29.9 kg/m2, p=0.05) when compared to those of non-excessive 
drinkers. As expected, excessive drinkers had higher AUDIT scores (26.9 vs 4.7, p<0.0001), 
greater total standard drinks in the past 30 days (257 vs 13 drinks, p<0.0001), higher average 
drinks per drinking day (12.9 vs 2.5 drinks, p<0.0001), and a higher number of drinking 
days in the past month (20 vs 4.5 days, p<0.001). Excessive drinkers had significantly higher 
levels of serum AST (35.2 vs 26.0 U/L, p=0.0002), GGT (85.5 vs 35.6 U/L, p<0.001), MCV 
(93.4 vs 89.4 fL, p=0.002) and %CDT (2.55 vs 1.63%, p<0.001). Higher concentrations of 
ALT were observed in non-excessive drinkers (50.7 vs 36.5 U/L, p<0.001).
Demographic and clinical characteristic of the validation sample resembled those of the 
training sample. Age, sex and race distributions of the study participants in the training and 
validation samples were similar. The cases in the two samples also had similar AUDIT-C 
scores as well as alcohol drinking patterns based on the TLFB.
Development of a composite screening score
Simple logistic regression models (ie, models with one predictor) were used to determine the 
significance of individual markers (table 3). The areas under the ROC curves associated with 
the individual markers were obtained from simple logistic regression analysis and reported 
in table 3. The AUC values of the individual markers ranged from 0.63 to 0.77, with CDT 
having the highest value.
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To develop the composite screening model, we used multivariate logistic regression. 
Different combinations of the individual markers were included in the separate logistic 
regression analysis, using data from the training sample.
The final model was selected based on the AIC. The model corresponding to the lowest AIC 
value included all markers except GGT. Adding GGT to the model resulted in an increase in 
AIC and the model became less stable numerically. Breslow-Lemeshow test indicated the 
selected model was not significantly different from the full model with all five markers.20
The regression coefficients and corresponding p values of the final model were tabulated in 
table 3. To ensure that the model does not suffer from multicollinearity, we examined the 
pairwise associations among the markers. ALT and AST had a moderate level of correlation 
(ρ=0.55); all other correlations were weaker. But these correlations did not cause model 
instability. VIF values were all below 2.0, indicating an absence of multicollinearity.
Using regression coefficients estimated from the training sample, we arrived at the following 
screening score:
The derived screening score (P) could be interpreted as an individual’s estimated probability 
of excessive drinking.
Determination of threshold value
The AUC value of the selected model was 0.87 (see figure 1A), indicating a strong 
discriminating power. Compared to the single marker screening models, the composite 
screening model had superior classification accuracy, as evidenced by its greater value of 
AUC (see table 3). Formal comparison of the AUC values of the single marker models and 
that of the selected model confirmed that the latter had significantly greater AUC value (all p 
values <0.0001). We determined the threshold values for screening of excessive drinking by 
examining the levels of sensitivity and specificity corresponding to the different threshold 
values. We compared the sensitivity and specificity of various threshold values, as shown in 
table 3. In situations where sensitivity and specificity are of equal interest, the value that 
maximizes sensitivity+specificity−1 (known as the Youden’s Index) is sometimes used as 
the cut-off.21 But due to the lack of universally accepted criteria for selecting optimal cut-off 
points, investigators often choose values that are most sensible to their applications. In the 
current study, we valued sensitivity more than specificity; so we chose a threshold value to 
ensure a good sensitivity. In particular, we noted that P score greater than 0.23 corresponded 
to a sensitivity of 90% and a specificity of nearly 60%. Lowering the threshold value would 
classify more patients as alcoholic, thus sensitizing the screener, at the expense of increased 
false positivity. For example, a threshold of 0.2 would increase the sensitivity to almost 94% 
while reducing specificity to 50% (table 4).
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Validation of the screening score and the selected threshold value
To validate the proposed screening model, we presented the estimated ROC curve in the 
independent validation sample. As shown in figure 1B, the AUC value remained at a 
respectable level of 0.83. Using 0.23 as the screening threshold, we estimated the screener’s 
sensitivity and specificity to be 91% and 49%, respectively, in the validation sample. The 
cross-validation study based on 20 resamples showed a mean AUC value of 0.88, thus 
confirming the predicative performance of the proposed screener.
DISCUSSION
Excessive alcohol use, if left undetected and untreated, could lead to significant health 
sequelae and devastating social consequences. Accurate screening for EAU, followed by 
appropriate counseling and patient abstinence, is essential for timely care of these patients.4 
Thorough interview, good history taking, and the use of standardized questionnaires are 
important during clinic encounters to screen for EAU.672223 However, a major weakness of 
the behavioral screening instruments is their suboptimal levels of sensitivity, which lead to 
significant portion of EAU undetected.24 It is therefore crucial to develop more sensitive and 
objective screening measures so that healthcare providers can properly assess the drinking 
status of their patients.
A number of laboratory tests have been routinely used as biomarkers indicative of a person’s 
alcohol intake. Several reflect the activity of the hepatic enzymes, such as AST, ALT and 
GGT.422 Other non-hepatic enzyme markers have been used, for example, MCV and 
%CDT.22 MCV, the volume of red blood cells, has also been shown to be positively 
associated with heavy drinking.22 Transferrin molecules in the blood usually contain several 
carbohydrate components. In chronic heavy drinkers, however, the number of carbohydrate 
components in each transferrin molecule is reduced, resulting in the increase in %CDT.9
These markers, when used individually for screening purposes, are often not sufficiently 
sensitive. As we have reported previously, the diagnostic performance of these markers left 
much to be desired.4 In this research, we constructed a composite screening tool by 
combining the commonly used biomarkers, in hope for an improved diagnostic performance. 
The resultant score was expressed as a function of AST, ALT, CDT and MCV. We showed 
that using a threshold value of 0.23, the proposed screening tool was able to achieve a high 
level of sensitivity (>90%), without greatly sacrificing the specificity (~60%). A validation 
study further confirmed the performance of the proposed screening method. The work has 
shown that it is possible to derive a much improved screening sensitivity by combining the 
markers into a composite measure, even when the individual markers are not sufficiently 
discriminant.
A few limitations deserve discussion. As previously mentioned, identifying the ‘true’ cases 
of EAU is challenging, given the fact that no ‘objective measurements’ exist. We thus used 
recruited subjects from the alcohol rehabilitation hospital as the true cases. As shown in 
tables 1 and 2, our cases had significantly higher AUDIT scores as well as reported quantity 
of alcohol consumption in the past 30 days using TLFB questionnaires. While the 
differences between the cases and non-cases are not unexpected, the separation could still 
Tu et al. Page 6
J Investig Med. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
influence the performance of the proposed screener. This said, we note that the diagnostic 
performance of individual markers in the same study sample has not been nearly as good, 
thus reassuring the advantages of the new screening tool. We also note that the excellent 
level of sensitivity of the proposed screener was achieved at the expense of lower specificity. 
For a screening tool we are mainly interested in maintaining a higher level of sensitivity, 
which allows us to more readily identify individuals at risk for EAU. Diagnostic decisions, 
however, will be made by care providers with additional clinical assessments, which help to 
compensate the lower specificity of the screener. Finally, considering the limited nature of 
our validation study, further investigations are needed to establish the generalisability of the 
proposed screener, and the appropriateness of the threshold values in different clinical 
populations.
Notwithstanding these limitations, we developed a novel composite score by using a 
combination of commonly used biomakers. However, the development of the mechanism-
based biomarkers of EAU is needed to improve the screening and diagnosis of EAU in 
clinical practice.
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Significance of this study
What is already known about this subject?
▸ Drinking becomes excessive when it causes/elevates the risk for alcohol-
related problems.
▸ Failure to detect excessive alcohol use in a timely fashion could delay 
intervention, and leads to serious sequelae.
▸ Reports from our research team and others clearly highlight the insufficient 
diagnostic accuracy of current non-invasive markers when they are used as a 
single marker for excessive alcohol use screening.
What are the new findings?
▸ A composite measure that combines the discriminant values of commonly 
used individual laboratory markers improves screening performance for 
excessive alcohol use.
▸ Our results need to be validated in a larger cohort.
How might these results change the focus of research?
▸ Further research to identify mechanism-based biomarkers to screen for 
excessive alcohol use is needed.
▸ The effects of ethanol on multiple organ systems are likely to reflect the 
changes in quantity or quality of constituents or novel serum proteins.
▸ These changes in the serum protein may serve as the potential biomarkers for 
excessive alcohol use.
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Figure 1. 
Receiver operating characteristic curves associated with the individual markers and the 
composite screener in the training and validation samples. (A) For the training dataset, the 
areas under the ROC curve (AUC) for ALT, AST, CDT, MCV, and the composite screener 
were 0.71, 0.63, 0.77, 0.66, and 0.87, respectively. (B) For the validation data, the AUC 
values for ALT, AST, CDT, MCV, and the composite screener were 0.79, 0.55, 0.53, 0.69 
and 0.83, respectively. ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
AUC, areas under the receiver operating characteristic curve; CDT, Carbohydrate-deficient 
transferrin; MCV, mean corpuscular volume; ROC, receiver operating characteristic curve.
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Table 1
Baseline demographic and alcohol drinking characteristics of the training cohort
Demographic and clinical characteristics Non-excessive drinkers (n=210) Excessive drinkers (n =272) p Value
Age (years) 32.47±8.58 39.73±11.80 <0.0001
Sex, male, n (%) 180 (85.71) 182 (66.91) <0.0001
Race, white, n (%) 168 (80.00) 220 (80.88)   0.8993
Marital status, n (%)   0.0001
 Married 114 (54.3) 96 (35.3)
 Divorced/separated 38 (18.1) 77 (28.3)
 Never married 40 (19.1) 76 (27.9)
 Others 18 (8.5) 23 (8.5)
BMI (kg/m2) 29.90±14.31 27.87±5.51   0.0538
AUDIT-C 4.72±5.67 26.89±7.75 <0.0001
Alcohol drinking patterns during the past 30 days from TLFB
 Total drinks 13.35±15.28 257.72±176.48 <0.0001
 Number of days drinking past 30 days 4.54±5.31 20.08±6.17 <0.0001
 Average drinks per drinking day 2.48±2.89 12.85±7.54 <0.0001
 Average drinks per day 0.45±0.51 8.59±5.88 <0.0001
 Greatest number of drinks in 1 day 3.87±4.22 18.60±8.92 <0.0001
BMI, body mass index; TLFB, Time Line Follow-Back.
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Table 2
Baseline demographic and alcohol drinking characteristics of the validation cohort
Demographic and clinical characteristics Non-excessive drinkers (n=75) Excessive drinkers (n =100) p Value
Age (years) 33.31±9.25 39.06±11.88   0.0004
Sex, male, n (%) 68 (90.67) 67 (67.00)   0.0004
Race, white, n (%) 61 (81.33) 81 (81.00)   1.0000
Marital status, n (%)   0.0070
 Married 44 (58.7) 44 (44)
 Divorced/separated 15 (20) 22 (22)
 Never married 9 (12) 28 (28)
 Others 7 (9.3) 6 (6)
BMI (kg/m2) 29.07±5.33 28.28±5.45   0.3441
AUDIT-C 4.93±6.46 26.71±7.70 <0.0001
Alcohol drinking patterns during the past 30 days from TLFB
 Total drinks 11.27±13.52 286.05±202.54 <0.0001
 Number of days drinking past 30 days 3.71±4.33 20.19±6.13 <0.0001
 Average drinks per drinking day 2.80±3.58 13.99±8.68 <0.0001
 Average drinks per day   0.38±0.45 9.53±6.75 <0.0001
 Greatest number of drinks in 1 day 4.11±4.59 19.73±9.52 <0.0001
BMI, body mass index.
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